Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Pharmacogenetics (London)

• Publication date

  2001-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00008571-200102000-00006PMID 11207030
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.

  1999cited by this paper
• Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes.

  1999cited by this paper
• Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.

  1998cited by this paper
• CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.

  1998cited by this paper
• Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.

  1998cited by this paper
• Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group.

  1998cited by this paper
• Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians.

  1998cited by this paper
• Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

  1997cited by this paper
• Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

  1997cited by this paper
• Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.

  1997cited by this paper
• Nomenclature for human CYP2D6 alleles.

  1996cited by this paper
• Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.

  1996cited by this paper
• Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.

  1996cited by this paper
• PCR-based genotyping for duplicated and deleted CYP2D6 genes.

  1996cited by this paper
• Characterization of the Human Cytochrome P4502D6 Promoter

  1996cited by this paper
• Ultrarapid metabolizers of debrisoquine: Characterization and PCR‐based detection of alleles with duplication of the CYP2D6 gene

  1996cited by this paper
• A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15.

  1996cited by this paper
• A retroviral element in the human CYP2D gene cluster.

  1996cited by this paper
• Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.

  1995cited by this paper
• An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.

  1995cited by this paper
• Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.

  1995cited by this paper
• Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population

  1995cited by this paper
• Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

  1995cited by this paper
• Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

  1994cited by this paper
• Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

  1993cited by this paper
• Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.

  1991cited by this paper
• The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

  1989cited by this paper
• A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

  1985cited by this paper
• Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation

  1985cited by this paper
• Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

  1982cited by this paper
• A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

  1980cited by this paper

• Glaucoma diagnosis and treatment in the era of precision medicine.

  2025cites this paper
• Pharmacogenetic Influences on Individual Responses to Ocular Hypotensive Agents in Glaucoma Patients

  2025cites this paper
• Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo

  2024cites this paper
• Genotype and Phenotype Influence the Personal Response to Prostaglandin Analogues and Beta-Blockers in Spanish Glaucoma and Ocular Hypertension Patients

  2023cites this paper
• Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population

  2020cites this paper
• Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?—Results from the ADRED Study

  2020cites this paper
• Characterization of CYP2D protein from human brain cerebellum

  2020cites this paper
• Pharmacogenomics in Palliative Medicine

  2019cites this paper
• Significantly lower CYP2D6 metabolism measured as the O/N‐desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients

  2018cites this paper
• Complications of Psychotropic and Pain Medications in an Ultrarapid Metabolizer Patient at the Upper 1% of Cytochrome P450 (CYP450) Function Quantified by Combinatorial CYP450 Genotyping

  2017cites this paper
• CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications

  2017cites this paper
• Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need

  2017cites this paper
• Clinical Implications of Opioid-Induced Hyperalgesia

  2016cites this paper
• Practical interpretation of CYP2D6 haplotypes: Comparison and integration of automated and expert calling.

  2016cites this paper
• Tamoxifen and Irinotecan Pharmacogenomics

  2014cites this paper
• Pharmacogenomics of methadone maintenance treatment.

  2014cites this paper
• Pharmacogenomics in Anesthesia

  2014cites this paper
• Chapter 4 – Drug Metabolism and Pharmacogenetics

  2013cites this paper
• CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.

  2013cites this paper
• CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence.

  2013cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders

  2013cites this paper
• The AmpliChip™ CYP450 Genotyping Test

  2012cites this paper
• CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene.

  2012cites this paper
• Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes

  2012cites this paper
• Frequency of Undetected CYP2D6 Hybrid Genes in Clinical Samples: Impact on Phenotype Prediction

  2012cites this paper
• Genetic polymorphism of drug metabolizing enzymes in the Shona and the San in Zimbabwe and the clinical impact of CYP2D6 polymorphism on safety in the use of psychotropics

  2012cites this paper
• Drug epidemiology, interactions and pharmacogenetics : A post-mortem database study

  2011cites this paper
• TOOLS IN PHARMACOVIGILANCE IN PSYCHIATRY: THERAPEUTIC DRUG MONITORING, PHARMACOGENETIC TESTS AND DRUG-DRUG INTERACTIONS DATABASES

  2011cites this paper
• Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

  2011cites this paper
• Regulatory genetic variation in the Flavin-containing monooxygenase 1 gene (FMO1) : detection and functional consequences

  2011cites this paper
• Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.

  2011cites this paper
• A post-mortem database study

  2011cites this paper
• Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study

  2011cites this paper
• Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions

  2011cites this paper
• Elucidation of CYP2D6 Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population

  2010cites this paper
• CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

  2010cites this paper
• Influence of CYP2D6 Deletion, Multiplication, –1584C→G, 31G→A and 2988G→A Gene Polymorphisms on Dextromethorphan Metabolism among Mexican Tepehuanos and Mestizos

  2010cites this paper
• Preliminary CommuniCation Preliminary CommuniCation CYP 2 D 6-1584 C > G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers

  2010cites this paper
• Pharmacogenomic variability and anaesthesia.

  2009cites this paper
• Pharmacogenomics of tamoxifen therapy.

  2009cites this paper
• Expression and Functional Analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 Isozymes

  2009cites this paper
• Qué necesita saber sobre los opiáceos

  2009cites this paper
• Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

  2009cites this paper
• The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

  2009cites this paper
• Expression and Functional Analysis of CYP 2 D 6 . 24 , CYP 2 D 6 . 26 , CYP 2 D 6 . 27 and CYP 2 D 7 Isozymes

  2008cites this paper
• Einfluss des Cytochrom P450 Enzyms CYP2D6 auf den Metabolismus von Methadon

  2008cites this paper
• The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans

  2008cites this paper
• What you need to know about opioids.

  2008cites this paper
• Variations in opioid responsiveness.

  2008cites this paper
• Genetic polymorphisms in the cytochrome P450 system and efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.

  2008cites this paper
• CYP2D6 a jeho klinický význam

  2008cites this paper
• Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.

  2008cites this paper
• Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition

  2008cites this paper
• Search for functional alleles in the human genome with focus on cardiovascular disease candidate genes.

  2007cites this paper
• Pharmacogenetics of Opioids

  2007cites this paper
• CYP2D6 A JEHO KLINICKÝ V ÝZNAM CYP2D6 A JEHO KLINICKÝ V ÝZNAM

  2007cites this paper
• The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.

  2007cites this paper
• The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.

  2007cites this paper
• Frequency of the Frame-Shifting CYP2D7 138delT Polymorphism in a Large, Ethnically Diverse Sample Population

  2007influential citation
• Phase I and Phase II Enzyme Polymorphisms and Childhood Cancer

  2006cites this paper
• AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry

  2006cites this paper
• Chapter 4 – Pharmacogenetics: Focus on the Liver

  2006cites this paper
• Molecular analysis of mechanisms leading to CYP2D6 intermediate and ultrarapid metabolizer phenotypes

  2006cites this paper
• AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

  2006cites this paper
• Prevention of Postoperative Nausea and Vomiting with Granisetron and Dolasetron in Relation to CYP2D6 Genotype

  2006cites this paper
• AmpliChip CYP450 GeneChip®: A New Gene Chip That Allows Rapid and Accurate CYP2D6 Genotyping

  2006cites this paper
• Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance

  2006cites this paper
• Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

  2006cites this paper
• The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.

  2006cites this paper
• Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN).

  2005cites this paper
• Genetics and psychopharmacology: prospects for individualized treatment.

  2005cites this paper
• COMMENT ON “A FRAMESHIFT MUTATION AND ALTERNATE SPLICING IN HUMAN BRAIN GENERATE A FUNCTIONAL FORM OF THE PSEUDOGENE CYTOCHROME P4502D7 THAT DEMETHYLATES CODEINE TO MORPHINE”

  2005cites this paper
• Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.

  2005cites this paper
• Presence of splice variant forms of cytochrome P4502D1 in rat brain but not in liver.

  2005cites this paper
• The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution.

  2005cites this paper
• Letter to the Editor COMMENT ON “A FRAMESHIFT MUTATION AND ALTERNATE SPLICING IN HUMAN BRAIN GENERATE A FUNCTIONAL FORM OF THE PSEUDOGENE CYTOCHROME P4502D7 THAT DEMETHYLATES CODEINE TO MORPHINE”

  2005cites this paper
• CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein?

  2005cites this paper
• Pharmacogenetics of the cytochromes P450.

  2004cites this paper
• Genes and the response to drugs.

  2004cites this paper
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cites this paper
• Genetic Predictors of the Clinical Response to Opioid Analgesics

  2004cites this paper
• Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics

  2004cites this paper
• A novel intronic mutation, 2988G>A, with high predictivity for impaired dunction of cytochrome P450 2D6 in white subjects

  2004cites this paper
• A Frameshift Mutation and Alternate Splicing in Human Brain Generate a Functional Form of the Pseudogene Cytochrome P4502D7 That Demethylates Codeine to Morphine*

  2004cites this paper
• 日本人におけるCYP2D6遺伝子多型解析についての再検討 : -1584C/G変異に基づく頻度解析

  2004cites this paper
• Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates

  2004cites this paper
• Chapter 13 - Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters

  2004cites this paper
• Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

  2004cites this paper
• Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.

  2004cites this paper
• Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene.

  2004cites this paper
• Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

  2003cites this paper
• Regulatory aspects of pharmacogenetics and pharmacogenomics

  2003cites this paper
• CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism.

  2003cites this paper
• Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing

  2003cites this paper
• Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR.

  2003cites this paper
• Reevaluation of formulas for predicting creatinine clearance in adults and children, using compensated creatinine methods.

  2003cites this paper
• L’importance clinique des interactions médicamenteuses reliées aux isoenzymes du cytochrome P450 : de la fiction à la réalité

  2003cites this paper
• Pharmacogenetics of the major polymorphic metabolizing enzymes

  2003cites this paper
• Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status.

  2003cites this paper
• Bioinformatics research on inter-racial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes.

  2003cites this paper